Menu
Recruiting NCT07234955

Minimally Invasive Surgery For Patients With Spontaneous Deep Intracerebral Hemorrhage

Observational Intracerebral Hemorrhage Basal Ganglia Intracerebral Haemorrhage

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Intracerebral Hemorrhage Basal Ganglia, Intracerebral Haemorrhage. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Vietnam
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation Of The Efficacy And Safety Of Minimally Invasive Surgery In Patients With Spontaneous Deep Intracerebral Hemorrhage

Overview

This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.

Detailed description

Spontaneous deep intracerebral hemorrhage (ICH) is associated with high early mortality and long-term disability. Conventional craniotomy has not consistently improved functional outcomes, while medical management alone often results in poor prognosis. Minimally invasive surgery (MIS), including parafascicular approaches guided by neuronavigation, is designed to evacuate hematomas with reduced disruption of critical white-matter tracts. Evidence supporting MIS is more robust in lobar ICH, whereas data for basal ganglia hemorrhage remain limited. Furthermore, most prior studies restricted surgical intervention to within 24 hours from onset, leaving uncertainty regarding potential benefit when performed between 24 and 72 hours.

This prospective, multicenter, observational cohort study is conducted at People's Hospital 115 and Tam Anh General Hospital. Consecutive patients admitted with spontaneous basal ganglia ICH are enrolled within 72 hours of onset. Decisions regarding MIS, including whether to operate and the timing of surgery, are made by treating clinical teams in routine practice. The study does not assign interventions but documents real-world management and outcomes.

Data are captured prospectively using standardized CRFs and electronic CRFs. Information includes demographics, comorbidities, presenting neurological status, laboratory and imaging findings, details of MIS when performed, intensive care and hospital course, and follow-up assessments through 180 days. The primary endpoint is functional outcome at 180 days, while safety endpoints include mortality and treatment-related complications. Analyses are planned using prespecified multivariable approaches to account for confounding by indication. Additional subgroup analyses will assess outcomes by timing of MIS (0-24 vs 24-72 hours) and other clinically relevant variables.

By focusing on basal ganglia hemorrhage in contemporary Vietnamese stroke centers, this study is intended to generate real-world evidence on the effectiveness and safety of MIS in deep ICH and inform selection criteria and timing for future interventional trials.

Primary outcome measures

  • Primary Outcome Measure 1 - Efficacy: Functional Outcome by Modified Rankin Scale (mRS) [Time frame: 180 days after intracerebral hemorrhage]
  • Primary Outcome Measure 2 - Efficacy: Functional Outcome by Utility-Weighted mRS (UW-mRS) [Time frame: 180 days after intracerebral hemorrhage]
  • Primary Outcome Measure 3 - Safety: All-Cause Mortality [Time frame: 30 days after intracerebral hemorrhage]
  • Primary Outcome Measure 4 - Safety: Procedure-Related Complications [Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage]
Secondary outcome measures (3)
  • Secondary Outcome Measure 1: Functional Outcome by Timing of MIS (0-24 Hours vs 24-72 Hours) [Time frame: 180 days after intracerebral hemorrhage]
  • Secondary Outcome Measure 2: All-Cause Mortality at 30 Days by Timing of MIS (0-24 Hours vs 24-72 Hours) [Time frame: 30 days after intracerebral hemorrhage]
  • Secondary Outcome Measure 3: Procedure-Related Complications by Timing of MIS (0-24 Hours vs 24-72 Hours) [Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage]

Eligibility criteria

Inclusion criteria

  • Age 18 to 80 years
  • Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT scan
  • Hematoma volume 30-80 mL (ABC/2 method)
  • Time from onset/last known well ≤ 72 hours
  • Glasgow Coma Scale (GCS) score 5-14 at admission
  • Pre-stroke modified Rankin Scale (mRS) score 0-1

Exclusion criteria

  • Secondary intracerebral hemorrhage due to trauma, tumor, vascular malformation, aneurysm, or hemorrhagic transformation of ischemic stroke
  • Infratentorial hemorrhage (brainstem or cerebellum)
  • Primary thalamic hemorrhage
  • Extensive intraventricular hemorrhage (>50% of one lateral ventricle)
  • NIHSS < 5 at admission
  • Bilateral fixed dilated pupils without light reflex
  • Decerebrate posture
  • Platelet count < 75,000/µL
  • INR > 1.4 after correction
  • Ongoing anticoagulation that cannot be rapidly reversed
  • Indication for long-term anticoagulation within 5 days of onset
  • End-stage renal disease
  • End-stage liver disease
  • Presence of mechanical heart valve
  • Any comorbidity with life expectancy < 6 months
  • Patient or legal representative unwilling or unable to provide written informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Vietnam · 1 center
  • People's Hospital 115 — Ho Chi Minh City

Identifiers

NCT: NCT07234955 · CS/15/25/48 · CS/15/25/48

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗